Idorsia Data Highlights Untapped Menopause Insomnia Market
Event summary
- Idorsia published data in *Maturitas* showing daridorexant (50mg) improved sleep and daytime functioning in women aged 47-55 with insomnia.
- The Phase 3 trial data revealed improvements of ~43 minutes in Wake After Sleep Onset (WASO), ~34 minutes in Latency to Persistent Sleep (LPS), and ~75 minutes in self-reported total sleep time.
- Brigham and Women’s Hospital will include daridorexant in the CELESTE study, comparing it to other menopause-related insomnia treatments.
- Idorsia will supply daridorexant at no cost to support the CELESTE study, funded by PCORI, which will enroll ~900 women over 60 months.
The big picture
The menopause transition affects a significant portion of the female population, and insomnia is a prevalent, often under-treated, symptom. Idorsia's data suggests a substantial unmet need and a potential market opportunity for targeted therapies. The CELESTE study, with its focus on diverse patient factors, could significantly influence treatment guidelines and physician prescribing habits, but also exposes the drug to comparative scrutiny.
What we're watching
- Market Adoption
- The CELESTE study results will be critical in determining whether daridorexant can gain significant market share within the underserved menopause-related insomnia segment.
- Regulatory Expansion
- How quickly Idorsia can leverage this data to expand daridorexant's label to specifically address menopause-related insomnia will impact peak sales potential.
- Competitive Landscape
- The CELESTE study's comparison of daridorexant to other treatments will reveal its relative efficacy and cost-effectiveness, shaping its competitive positioning.
Related topics